Characteristics of α-Gal epitope, anti-Gal antibody, α1,3 galactosyltransferase and its clinical exploitation (Review)

Huai,Guoli; Qi,Ping; Yang,Hongji; Wang,Yi

doi:10.3892/ijmm.2015.2397

Characteristics of α-Gal epitope, anti-Gal antibody, α1,3 galactosyltransferase and its clinical exploitation (Review)

Authors:
- Guoli Huai
- Ping Qi
- Hongji Yang
- Yi Wang
View Affiliations

Affiliations: Department of Biomedical Engineering, Medical School of University of Electronic Science and Technology of China, Chengdu, Sichuan 610054, P.R. China, Department of Pediatrics, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China, Department of Pharmacy, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China
Published online on: October 30, 2015 https://doi.org/10.3892/ijmm.2015.2397
Pages: 11-20
Copyright: © Huai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The α-Gal epitope (Galα1,3Galα1,4GlcNAc‑R) is ubiquitously presented in non-primate mammals, marsupials and New World Monkeys, but it is absent in humans, apes and Old World monkeys. However, the anti-Gal antibody (~1% of immunoglobulins) is naturally generated in human, and is found as the immunoglobulin G (IgG), IgM and IgA isotypes. Owing to the specific binding of the anti‑Gal antibody with the α‑Gal epitope, humans have a distinct anti‑α‑gal reactivity, which is responsible for hyperacute rejection of organs transplanted from α‑gal donors. In addition, the α1,3 galactosyltransferases (α1,3GT) can catalyze the synthesis of the α‑Gal epitope. Therefore, the α1,3GT gene, which encodes the α1,3GT, is developed profoundly. The distributions of the α‑Gal epitope and anti‑Gal antibody, and the activation of α1,3GT, reveal that the enzyme of α1,3GT in ancestral primates is ineffective. Comparison of the nucleotide sequence of the human α1,3‑GT pseudogene to the corresponding different species sequence, and according to the evolutionary tree of different species, the results of evolutionary inactivation of the α1,3GT gene in ancestral primates attribute to the mutations under a stronger selective pressure. However, on the basis of the structure, the mechanism and the specificity of the α‑Gal epitope and anti‑Gal antibody, they can be applied to clinical exploitation. Knocking out the α1,3GT gene will eliminate the xenoantigen, Gal(α1,3)Gal, so that the transplantation of α1,3GT gene knockout pig organ into human becomes a potential clinically acceptable treatment for solving the problem of organ shortage. By contrast, the α‑Gal epitope expressed through the application of chemical, biochemical and genetic engineering can be exploited for the clinical use. Targeting anti‑Gal‑mediated autologous tumor vaccines, which express α‑Gal epitope to antigen‑presenting cells, would increase their immunogenicity and elicit an immune response, which will be potent enough to eradicate the residual tumor cells. For tumor vaccines, the way of increasing immunogenicity of certain viral vaccines, including flu vaccines and human immunodeficiency virus vaccines, can also be used in the elderly. Recently, α‑Gal epitope nanoparticles have been applied to accelerate wound healing and further directions on regeneration of internally injured tissues.

View Figures

View References

1	Boix E, Zhang Y, Swaminathan GJ, Brew K and Acharya KR: Structural basis of ordered binding of donor and acceptor substrates to the retaining glycosyltransferase, alpha-1,3-galacto-syltransferase. J Biol Chem. 277:28310–28318. 2002. View Article : Google Scholar : PubMed/NCBI
2	Shao Y, Yu Y, Pei CG, Qu Y, Gao GP, Yang JL, Zhou Q, Yang L and Liu QP: The expression and distribution of α-Gal gene in various species ocular surface tissue. Int J Ophthalmol. 5:543–548. 2012.
3	Galili U: The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. Immunol Cell Biol. 83:674–686. 2005. View Article : Google Scholar : PubMed/NCBI
4	Blanken WM and Van den Eijnden DH: Biosynthesis of terminal Gal alpha 1→3Gal beta 1→4GlcNAc-R oligosaccharide sequences on glycoconjugates. Purification and acceptor specificity of a UDP-Gal:N-acetyllactosaminide alpha 1→3-galactosyltrans-ferase from calf thymus. J Biol Chem. 260:12927–12934. 1985.PubMed/NCBI
5	Taylor SG, McKenzie IF and Sandrin MS: Characterization of the rat alpha(1,3)galactosyltransferase: evidence for two independent genes encoding glycosyltransferases that synthesize Galalpha(1,3)Gal by two separate glycosylation pathways. Glycobiology. 13:327–337. 2003. View Article : Google Scholar : PubMed/NCBI
6	Joziasse DH, Shaper JH, Jabs EW and Shaper NL: Characterization of an alpha 1→3-galactosyltransferase homologue on human chromosome 12 that is organized as a processed pseudogene. J Biol Chem. 266:6991–6998. 1991.PubMed/NCBI
7	Church DM, Goodstadt L, Hillier LW, Zody MC, Goldstein S, She X, Bult CJ, Agarwala R, Cherry JL, DiCuccio M, et al: Mouse Genome Sequencing Consortium: Lineage-specific biology revealed by a finished genome assembly of the mouse. PLoS Biol. 7:e10001122009. View Article : Google Scholar
8	Strahan KM, Gu F, Preece AF, Gustavsson I, Andersson L and Gustafsson K: cDNA sequence and chromosome localization of pig alpha 1,3 galactosyltransferase. Immunogenetics. 41:101–105. 1995. View Article : Google Scholar : PubMed/NCBI
9	Zimin AV, Delcher AL, Florea L, Kelley DR, Schatz MC, Puiu D, Hanrahan F, Pertea G, Van Tassell CP, Sonstegard TS, et al: A whole-genome assembly of the domestic cow, Bos taurus. Genome Biol. 10:R422009. View Article : Google Scholar : PubMed/NCBI
10	Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, Clamp M, Chang JL, Kulbokas EJ III, Zody MC, et al: Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature. 438:803–819. 2005. View Article : Google Scholar : PubMed/NCBI
11	Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, et al: International Human Genome Sequencing Consortium: Initial sequencing and analysis of the human genome. Nature. 409:860–921. 2001. View Article : Google Scholar : PubMed/NCBI
12	Galili U: Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody. Springer Semin Immunopathol. 15:155–171. 1993. View Article : Google Scholar : PubMed/NCBI
13	Larsen RDR-MC, Rivera-Marrero CA, Ernst LK, Cummings RD and Lowe JB: Frameshift and nonsense mutations in a human genomic sequence homologous to a murine UDP-Gal:beta-D-G al(1,4)-D-GlcNAc alpha(1,3)-galactosyltransferase cDNA. J Biol Chem. 265:7055–7061. 1990.PubMed/NCBI
14	Rodriguez IA and Welsh RM: Possible role of a cell surface carbohydrate in evolution of resistance to viral infections in old world primates. J Virol. 87:8317–8326. 2013. View Article : Google Scholar : PubMed/NCBI
15	Hamanova M, Chmelikova M, Nentwich I, Thon V and Lokaj J: Anti-Gal IgM, IgA and IgG natural antibodies in childhood. Immunol Lett. 164:40–43. 2015. View Article : Google Scholar : PubMed/NCBI
16	Wang L, Radic MZ and Galili U: Human anti-Gal heavy chain genes. Preferential use of VH3 and the presence of somatic mutations. J Immunol. 155:1276–1285. 1995.PubMed/NCBI
17	Commins SP and Platts-Mills TA: Delayed anaphylaxis to red meat in patients with IgE specific for galactose alpha-1,3-ga-lactose (alpha-gal). Curr Allergy Asthma Rep. 13:72–77. 2013. View Article : Google Scholar :
18	Galili U, LaTemple DC and Radic MZ: A sensitive assay for measuring alpha-Gal epitope expression on cells by a monoclonal anti-Gal antibody. Transplantation. 65:1129–1132. 1998. View Article : Google Scholar : PubMed/NCBI
19	LaTemple DC and Galili U: Adult and neonatal anti-Gal response in knock-out mice for alpha1,3galactosyltransferase. Xenotransplantation. 5:191–196. 1998. View Article : Google Scholar : PubMed/NCBI
20	Park S, Kim WH, Choi SY and Kim YJ: Removal of alpha-Gal epitopes from porcine aortic valve and pericardium using recombinant human alpha galactosidase A. J Korean Med Sci. 24:1126–1131. 2009. View Article : Google Scholar : PubMed/NCBI
21	Abdel-Motal UM, Guay HM, Wigglesworth K, Welsh RM and Galili U: Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells. J Virol. 81:9131–9141. 2007. View Article : Google Scholar : PubMed/NCBI
22	Gurtner GCWS, Werner S, Barrandon Y and Longaker MT: Wound repair and regeneration. Nature. 453:314–321. 2008. View Article : Google Scholar : PubMed/NCBI
23	LaTemple DC, Henion TR, Anaraki F and Galili U: Synthesis of alpha-galactosyl epitopes by recombinant alpha1,3galactosyl transferase for opsonization of human tumor cell vaccines by anti-galactose. Cancer Res. 56:3069–3074. 1996.PubMed/NCBI
24	Singer AJ and Clark RA: Cutaneous wound healing. N Engl J Med. 341:738–746. 1999. View Article : Google Scholar : PubMed/NCBI
25	Sandrin MS, Osman N and McKenzie IF: Transgenic approaches for the reduction of Galalpha(1,3)Gal for xenotransplantation. Front Biosci. 2:e1–11. 1997.PubMed/NCBI
26	Osman N, McKenzie IF, Mouhtouris E and Sandrin MS: Switching amino-terminal cytoplasmic domains of alpha(1,2) fucosyltransferase and alpha(1,3)galactosyltransferase alters the expression of H substance and Galalpha(1,3)Gal. J Biol Chem. 271:33105–33109. 1996. View Article : Google Scholar : PubMed/NCBI
27	Xing L, Xia GH, Fei J, Huang F and Guo LH: Adenovirus-mediated expression of pig alpha(1,3) galactosyltransferase reconstructs Gal alpha(1, 3) gal epitope on the surface of human tumor cells. Cell Res. 11:116–124. 2001. View Article : Google Scholar : PubMed/NCBI
28	Liu M, Zhu SM, Zheng H, Wang Y, Wang Z, Yang YJ, Wu YX, Zeng YZ and Wang YP: Cloning of splicing variants of alpha1,3-galactosyltransferase cDNA of Chinese Banna Minipig inbred line and its expression in human cells. Sichuan Da Xue Xue Bao Yi Xue Ban. 43:145–150. 2012.In Chinese. PubMed/NCBI
29	Joziasse DH, Shaper JH, Van den Eijnden DH, Van Tunen AJ and Shaper NL: Bovine alpha 1→3-galactosyltransferase: Isolation and characterization of a cDNA clone. Identification of homologous sequences in human genomic DNA. J Biol Chem. 264:14290–14297. 1989.PubMed/NCBI
30	Lantéri M, Giordanengo V, Vidal F, Gaudray P and Lefebvre JC: A complete alpha1,3-galactosyltransferase gene is present in the human genome and partially transcribed. Glycobiology. 12:785–792. 2002. View Article : Google Scholar : PubMed/NCBI
31	Galili U and Swanson K: Gene sequences suggest inactivation of alpha-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys. Proc Natl Acad Sci USA. 88:7401–7404. 1991. View Article : Google Scholar : PubMed/NCBI
32	Ma YH, Zhou XG, Hu JH, Fei J, Xia GH and Guo LH: Human xenoreactivity is reduced in mice bearing porcine antisense alpha(1,3) galactosyltransferase cDNA. Acta Pharmacol Sin. 22:231–238. 2001.PubMed/NCBI
33	Galili U and Andrews P: Suppression of a-galactosyl epitopes synthesis and production of the natural anti-Gal antibody: A major evolutionary event in ancestral Old World primates. J Hum Evol. 29:433–442. 1995. View Article : Google Scholar
34	Fang J, Walters A, Hara H, Long C, Yeh P, Ayares D, Cooper DK and Bianchi J: Anti-gal antibodies in α1,3-galactosyltransferase gene-knockout pigs. Xenotransplantation. 19:305–310. 2012. View Article : Google Scholar : PubMed/NCBI
35	Koike C, Fung JJ, Geller DA, Kannagi R, Libert T, Luppi P, Nakashima I, Profozich J, Rudert W, Sharma SB, et al: Molecular basis of evolutionary loss of the alpha 1,3-galac-tosyltransferase gene in higher primates. J Biol Chem. 277:10114–10120. 2002. View Article : Google Scholar : PubMed/NCBI
36	Sandrin MS, Vaughan HA, Dabkowski PL and McKenzie IF: Anti-pig IgM antibodies in human serum react predominantly with Gal(alpha 1–3) Gal epitopes. Proc Natl Acad Sci USA. 90:11391–11395. 1993. View Article : Google Scholar
37	Galili U, Rachmilewitz EA, Peleg A and Flechner I: A unique natural human IgG antibody with anti-a-galactosyl specificity. J Exp Med. 160:1519–1581. 1984. View Article : Google Scholar : PubMed/NCBI
38	Galili U: Anti-Gal: An abundant human natural antibody of multiple pathogeneses and clinical benefits. Immunology. 140:1–11. 2013. View Article : Google Scholar : PubMed/NCBI
39	Galili U: Significance of the evolutionary α1,3-galacto-syltransferase (GGTA1) gene inactivation in preventing extinction of apes and old world monkeys. J Mol Evol. 80:1–9. 2015. View Article : Google Scholar
40	Ma YH1, Zhou XG, Hu JH, Fei J, Xia GH and Guo LH: Human xeno-reactivity is reduced in mice bearing porcine antisense alpha(1,3) galactosyltransferase cDNA. Acta Pharmacol Sin. 22:231–238. 2001.PubMed/NCBI
41	Celis E, Abraham KG and Miller RW: Modulation of the immunological response to hepatitis B virus by antibodies. Hepatology. 7:563–568. 1987. View Article : Google Scholar : PubMed/NCBI
42	Byrne GW, Stalboerger PG, Du Z, Davis TR and McGregor CG: Identification of new carbohydrate and membrane protein antigens in cardiac xenotransplantation. Transplantation. 91:287–292. 2011. View Article : Google Scholar
43	Galili U: Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: A major obstacle for xenotransplan-tation in humans. Immunol Today. 14:480–482. 1993. View Article : Google Scholar : PubMed/NCBI
44	Anderson M: Xenotransplantation: A bioethical evaluation. J Med Ethics. 32:205–208. 2006. View Article : Google Scholar : PubMed/NCBI
45	Lee C, Ahn H, Kim SH, Choi SY and Kim YJ: Immune response to bovine pericardium implanted into α1,3-galactosyltransferase knockout mice: feasibility as an animal model for testing efficacy of anticalcification treatments of xenografts. Eur J Cardiothorac Surg. 42:164–172. 2012. View Article : Google Scholar : PubMed/NCBI
46	Kim YG, Gil GC, Harvey DJ and Kim BG: Structural analysis of alpha-Gal and new non-Gal carbohydrate epitopes from specific pathogen-free miniature pig kidney. Proteomics. 8:2596–2610. 2008. View Article : Google Scholar : PubMed/NCBI
47	Park CS, Oh SS, Kim YE, Choi SY, Lim HG, Ahn H and Kim YJ: Anti-alpha-Gal antibody response following xenogeneic heart valve implantation in adults. J Heart Valve Dis. 22:222–229. 2013.PubMed/NCBI
48	Wilczek P, Lesiak A, Niemiec-Cyganek A, Kubin B, Slomski R, Nozynski J, Wilczek G, Mzyk A and Gramatyka M: Biomechanical properties of hybrid heart valve prosthesis utilizing the pigs that do not express the galactose-α-1,3-galactose (α-Gal) antigen derived tissue and tissue engineering technique. J Mater Sci Mater Med. 26(5329)2015. View Article : Google Scholar
49	Choi SY, Jeong HJ, Lim HG, Park SS, Kim SH and Kim YJ: Elimination of alpha-gal xenoreactive epitope: Alpha-galactosidase treatment of porcine heart valves. J Heart Valve Dis. 21:387–397. 2012.PubMed/NCBI
50	Konakci KZ, Bohle B, Blumer R, Hoetzenecker W, Roth G, Moser B, Boltz-Nitulescu G, Gorlitzer M, Klepetko W, Wolner E, et al: Alpha-Gal on bioprostheses: Xenograft immune response in cardiac surgery. Eur J Clin Invest. 35:17–23. 2005. View Article : Google Scholar : PubMed/NCBI
51	Collins BH, Cotterell AH, McCurry KR, Alvarado CG, Magee JC, Parker W and Platt JL: Cardiac xenografts between primate species provide evidence for the importance of the alpha-galactosyl determinant in hyperacute rejection. J Immunol. 154:5500–5510. 1995.PubMed/NCBI
52	Manji RA, Menkis AH, Ekser B and Cooper DK: Porcine bioprosthetic heart valves: The next generation. Am Heart J. 164:177–185. 2012. View Article : Google Scholar : PubMed/NCBI
53	Tazelaar HD, Byrne GW and McGregor CG: Comparison of Gal and non-Gal-mediated cardiac xenograft rejection. Transplantation. 91:968–975. 2011. View Article : Google Scholar : PubMed/NCBI
54	Lim HG, Choi SY, Yoon EJ, Kim SH and Kim YJ: In vivo efficacy of alpha-galactosidase as possible promise for prolonged durability of bioprosthetic heart valve using alpha1,3-galactosyl-transferase knockout mouse. Tissue Eng Part A. 19:2339–2348. 2013. View Article : Google Scholar : PubMed/NCBI
55	McGregor CG, Carpentier A, Lila N, Logan JS and Byrne GW: Cardiac xenotransplantation technology provides materials for improved bioprosthetic heart valves. J Thorac Cardiovasc Surg. 141:269–275. 2011. View Article : Google Scholar
56	Mangold A, Szerafin T, Hoetzenecker K, Hacker S, Lichtenauer M, Niederpold T, Nickl S, Dworschak M, Blumer R, Auer J, et al: Alpha-Gal specific IgG immune response after implantation of bioprostheses. Thorac Cardiovasc Surg. 57:191–195. 2009. View Article : Google Scholar : PubMed/NCBI
57	Nam J, Choi SY, Sung SC, Lim HG, Park SS, Kim SH and Kim YJ: Changes of the structural and biomechanical properties of the bovine pericardium after the removal of α-Gal epitopes by decellularization and α-galactosidase treatment. Korean J Thorac Cardiovasc Surg. 45:380–389. 2012. View Article : Google Scholar :
58	Kasimir MT, Rieder E, Seebacher G, Wolner E, Weigel G and Simon P: Presence and elimination of the xenoantigen gal (alpha1, 3) gal in tissue-engineered heart valves. Tissue Eng. 11:1274–1280. 2005. View Article : Google Scholar : PubMed/NCBI
59	McGregor CG, Davies WR, Oi K, Teotia SS, Schirmer JM, Risdahl JM, Tazelaar HD, Kremers WK, Walker RC, Byrnew GW, et al: Cardiac xenotransplantation: Recent preclinical progress with 3-month median survival. J Thorac Cardiovasc Surg. 130:844–851. 2005. View Article : Google Scholar : PubMed/NCBI
60	Milland J, Christiansen D, Lazarus BD, Taylor SG, Xing PX and Sandrin MS: The molecular basis for galalpha(1,3)gal expression in animals with a deletion of the alpha1,3galactosyltransferase gene. J Immunol. 176:2448–2454. 2006. View Article : Google Scholar : PubMed/NCBI
61	Puga Yung G, Schneider MK and Seebach JD: Immune responses to alpha1,3 galactosyltransferase knockout pigs. Curr Opin Organ Transplant. 14:154–160. 2009. View Article : Google Scholar : PubMed/NCBI
62	Stone KR, Abdel-Motal UM, Walgenbach AW, Turek TJ and Galili U: Replacement of human anterior cruciate ligaments with pig ligaments: A model for anti-non-gal antibody response in long-term xenotransplantation. Transplantation. 83:211–219. 2007. View Article : Google Scholar : PubMed/NCBI
63	Park HM, Kim YW, Kim KJ, Kim YJ, Yang YH, Jin JM, Kim YH, Kim BG, Shim H and Kim YG: Comparative N-linked glycan analysis of wild-type and α1,3-galactosyltransferase gene knock-out pig fibroblasts using mass spectrometry approaches. Mol Cells. 38:65–74. 2015.
64	Macher BA and Galili U: The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: A carbohydrate of unique evolution and clinical relevance. Biochim Biophys Acta. 1780:75–88. 2008. View Article : Google Scholar
65	Deriy L, Chen ZC, Gao GP and Galili U: Expression of alpha-gal epitopes on HeLa cells transduced with adenovirus containing alpha1,3galactosyltransferase cDNA. Glycobiology. 12:135–144. 2002. View Article : Google Scholar : PubMed/NCBI
66	Naso F, Gandaglia A, Bottio T, Tarzia V, Nottle MB, d'Apice AJ, Cowan PJ, Cozzi E, Galli C, Lagutina I, et al: First quantification of alpha-Gal epitope in current glutaraldehyde-fixed heart valve bioprostheses. Xenotransplantation. 20:252–261. 2013. View Article : Google Scholar : PubMed/NCBI
67	Galili U: Conversion of tumors into autologous vaccines by intra-tumoral injection of α-Gal glycolipids that induce anti-Gal/α-Gal epitope interaction. Clin Dev Immunol. 2011(134020)2011. View Article : Google Scholar
68	Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D and Levitsky H: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 264:961–965. 1994. View Article : Google Scholar : PubMed/NCBI
69	Manca F, Fenoglio D, Li Pira G, Kunkl A and Celada F: Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies. J Exp Med. 173:37–48. 1991. View Article : Google Scholar : PubMed/NCBI
70	Abdel-Motal UM, Wigglesworth K and Galili U: Intratumoral injection of alpha-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity. Cancer Immunol Immunother. 58:1545–1556. 2009. View Article : Google Scholar : PubMed/NCBI
71	Schweighoffer T, Schmidt W, Buschle M and Birnstiel ML: Depletion of naive T cells of the peripheral lymph nodes abrogates systemic antitumor protection conferred by IL-2 secreting cancer vaccines. Gene Ther. 3:819–824. 1996.PubMed/NCBI
72	Liu C1, Gosselin EJ and Guyre PM: Fc gamma RII on human B cells can mediate enhanced antigen presentation. Cell Immunol. 167:188–194. 1996. View Article : Google Scholar : PubMed/NCBI
73	LaTemple DC, Abrams JT, Zhang SY and Galili U: Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase. Cancer Res. 59:3417–3423. 1999.PubMed/NCBI
74	Tanida T, Tanemura M, Miyoshi E, Nagano H, Furukawa K, Nonaka Y, Akita H, Hama N, Wada H, Kawamoto K, et al: Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express α-gal epitopes, targets pancreatic cancer stem cells. Int J Oncol. 46:78–90. 2015.
75	Tanemura M, Miyoshi E, Nagano H, Eguchi H, Taniyama K, Kamiike W, Mori M and Doki Y: Role of α-gal epitope/anti-Gal antibody reaction in immunotherapy and its clinical application in pancreatic cancer. Cancer Sci. 104:282–290. 2013. View Article : Google Scholar
76	Deguchi T, Tanemura M, Miyoshi E, Nagano H, Machida T, Ohmura Y, Kobayashi S, Marubashi S, Eguchi H, Takeda Y, et al: Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: A novel approach to immunotherapy in pancreatic cancer. Cancer Res. 70:5259–5269. 2010. View Article : Google Scholar : PubMed/NCBI
77	Whalen GF, Sullivan M, Piperdi B, Wasseff W and Galili U: Cancer immunotherapy by intratumoral injection of α-gal glyco-lipids. Anticancer Res. 32:3861–3868. 2012.PubMed/NCBI
78	Galili U, Repik PM, Anaraki F, Mozdzanowska K, Washko G and Gerhard W: Enhancement of antigen presentation of influenza virus hemagglutinin by the natural human anti-Gal antibody. Vaccine. 14:321–328. 1996. View Article : Google Scholar : PubMed/NCBI
79	Henion TR, Gerhard W, Anaraki F and Galili U: Synthesis of alpha-gal epitopes on influenza virus vaccines, by recombinant alpha 1,3galactosyltransferase, enables the formation of immune complexes with the natural anti-Gal antibody. Vaccine. 15:1174–1182. 1997. View Article : Google Scholar : PubMed/NCBI
80	Abdel-Motal U, Wang S, Lu S, Wigglesworth K and Galili U: Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes. J Virol. 80:6943–6951. 2006. View Article : Google Scholar : PubMed/NCBI
81	Hurwitz ZIR, Lalikos J and Galili U: Accelerated porcine wound healing with a-Gal nanoparticles. Plast Reconstr Surg. 129:242–251. 2012. View Article : Google Scholar
82	Galili U: Discovery of the natural anti-Gal antibody and its past and future relevance to medicine. Xenotransplantation. 20:138–147. 2013.PubMed/NCBI
83	Wigglesworth KM, Racki WJ, Mishra R, Szomolanyi-Tsuda E, Greiner DL and Galili U: Rapid recruitment and activation of macrophages by anti-Gal/α-Gal liposome interaction accelerates wound healing. J Immunol. 186:4422–4432. 2011. View Article : Google Scholar : PubMed/NCBI
84	Galili U, Wigglesworth K and Abdel-Motal UM: Accelerated healing of skin burns by anti-Gal/alpha-gal liposomes interaction. Burns. 36:239–251. 2010. View Article : Google Scholar